Allergy Shots for Tree Pollen: Birch, Oak, Cedar and the OAS Connection
Allergy shots for tree pollen are SCIT formulated against the specific tree species — birch, oak, alder, hazel, hornbeam, maple, cedar — to which a patient is IgE-sensitized. Birch SCIT has the best evidence (Bødtger 2002: ~40% symptom reduction); the Bet v 1 / PR-10 family creates cross-reactivity across most Northeast spring trees plus oral allergy syndrome foods. Mountain cedar conventional RCT base is thin (Thompson 2020 proof-of-concept only). No FDA-approved US tree-pollen SLIT tablet exists.
6 peer-reviewed sources
Tree pollen SCIT targets specific species confirmed by IgE testing. Birch has the strongest evidence (~40% reduction, Bødtger 2002). Bet v 1 PR-10 cross-reactivity unifies most Northeast spring trees. Cedar SCIT evidence is limited. No FDA-approved US tree-pollen SLIT tablet exists.
The essentials
Allergy shots for tree pollen are SCIT formulated against the specific tree species to which a patient's IgE testing shows sensitization — and the clinical story of tree pollen allergy in the US is largely the Bet v 1 / PR-10 protein family story.
Curex's at-home IgE testing maps a patient's tree-pollen sensitization — birch, oak, alder, hazel, hornbeam, cedar — and the cross-reactive PR-10 food homologs implicated in oral allergy syndrome, with allergist review to clarify the clinical picture. For eligible patients, Curex's at-home allergy shot kit ($129/month) delivers personalized tree-pollen SCIT — serum sterile-compounded to USP <797>, self-administered weekly at home with Zoom-supervised first dose.
Birch is the index tree allergen. Bødtger 2002 Allergy documented approximately 40% symptom-score reduction and approximately 50% medication-score reduction in a 1-year double-blind placebo-controlled birch SCIT RCT. Arvidsson 2002 JACI confirmed airway-symptom and medication reduction in a 2-year birch SCIT trial. The mechanism is the same as for all pollen SCIT: IgG4 blocking antibodies, Treg expansion, and progressive decline in IgE-mediated reactivity to Bet v 1.
The Bet v 1 / PR-10 cross-reactivity is the clinical signature of tree-pollen allergy. Birch, alder (Aln g 1), hazel (Cor a 1.04), oak (Que a 1), hornbeam, maple, and beech all share IgE cross-reactive epitopes with Bet v 1. A patient with documented birch sensitization typically shows IgE positivity across the entire PR-10 family on component testing — not because they are independently sensitized to each species, but because Bet v 1-reactive IgE cross-binds all PR-10 homologs. Component-resolved testing (ImmunoCAP Bet v 1) clarifies whether a "tree-allergic" patient is primarily birch-driven or has independent sensitizations to other species.
Oral allergy syndrome (OAS) — also called pollen-food syndrome — is the clinical consequence of Bet v 1 cross-reactivity with food PR-10 homologs. Birch-sensitized patients commonly react to: raw apple (cross-reactant Mal d 1), hazelnut (Cor a 1.04), raw cherry (Pru av 1), peach (Pru p 1), plum, raw carrot, and celery — tingling, itching, or mild swelling of the lips and oral mucosa. Cooking destroys most PR-10 epitopes (they are heat-labile); a patient who cannot eat a raw apple can typically eat cooked apple or applesauce without symptoms. Raw hazelnut is the notable exception — Cor a 8 (a lipid transfer protein) in hazelnut is heat-stable and can cause systemic reactions. Birch SCIT has been reported in observational studies to improve OAS symptoms over time, though RCT evidence for this effect is limited.
Mountain cedar (Juniperus ashei) is the most important exception to the birch-dominated tree-pollen story. Cedar fever affects millions in Texas and Oklahoma with peak season December–February — among the highest documented airborne pollen loads in North America. Cedar SCIT is practiced clinically, but the conventional RCT base is thin: Thompson 2020 (Ann Allergy Asthma Immunol 2020;125:311-318) documented intralymphatic cedar immunotherapy as proof-of-concept. Conventional cedar SCIT is extrapolated from grass and ragweed evidence; patients should be informed of this uncertainty at the time of treatment initiation.
A key practical point: no FDA-approved SLIT tablet for any tree pollen exists in the US as of this writing. Itulazax (birch pollen tablet, ALK) has EMA approval in Europe but is not FDA-approved. Tree-pollen-allergic patients in the US who prefer sublingual options must use compounded SLIT drops (off-label); those choosing SCIT can access the at-home Curex program for eligible patients.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Tree pollen SCIT efficacy is anchored by birch data; other tree pollens are largely extrapolated from birch via the PR-10 cross-reactivity mechanism.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
What tree pollens can allergy shots treat?
SCIT can be formulated for most tree pollens using standardized or non-standardized extracts. Birch has the strongest RCT evidence base (Bødtger 2002, Arvidsson 2002). Oak, alder, hazel, hornbeam, and maple share Bet v 1 / PR-10 cross-reactivity with birch — patients sensitized to birch typically show IgE positivity across this whole group. Mountain cedar (Juniperus ashei) SCIT is practiced clinically in Texas and Oklahoma but the conventional RCT base is thin. For patients primarily birch-sensitized, SCIT targeting birch extract may provide cross-protective benefit for other PR-10 family trees without requiring separate extracts for each species.
Can allergy shots help oral allergy syndrome from tree pollen?
Some patients with birch SCIT have reported improvement in oral allergy syndrome (OAS) symptoms — tingling, itching, or mild oral swelling from raw apples, hazelnuts, cherries, or peaches — but RCT evidence for SCIT as a primary OAS treatment is limited. OAS results from IgE cross-reactivity between Bet v 1 (birch) and PR-10 food homologs (Mal d 1 apple, Cor a 1 hazelnut, Pru av 1 cherry). As SCIT reduces overall Bet v 1 sensitization over years, cross-reactive food reactivity may diminish secondarily. OAS alone — without co-existing severe rhinitis or asthma — is generally not a primary indication for SCIT; the risks and 3–5 year commitment should be weighed against the benefit of simply cooking apple-containing foods or avoiding raw hazelnuts.
Is there an allergy shot for cedar fever in Texas?
Yes, mountain cedar (Juniperus ashei) SCIT is practiced clinically in Texas and Oklahoma, where cedar fever peaks December–February with pollen loads among the highest documented in North America. However, the conventional SCIT RCT base for Juniperus ashei is thin — Thompson 2020 (Ann Allergy Asthma Immunol 2020;125:311-318) documented intralymphatic cedar immunotherapy as proof-of-concept data only. Clinical practice extrapolates efficacy from the grass and ragweed SCIT literature. Patients undertaking cedar SCIT should be informed of this evidence gap at initiation. A non-standardized cedar extract is used; FDA-standardized cedar extract is not available.
Why do I react to raw apples if I have tree pollen allergy?
Raw apple reactions in birch-sensitized patients are oral allergy syndrome (OAS) caused by Bet v 1 / PR-10 cross-reactivity. The major birch allergen Bet v 1 shares structural homology with Mal d 1 (the major apple allergen) and other PR-10 proteins in raw stone fruits, hazelnuts, carrots, and celery. Your immune system's IgE against Bet v 1 cross-binds these food PR-10 proteins, causing tingling and oral pruritus — usually mild, occasionally severe. Cooking destroys PR-10 protein structure (they are heat-labile), so the same patient who reacts to a raw apple can typically eat cooked apple safely. Raw hazelnut is riskier due to the heat-stable Cor a 8 lipid transfer protein, which can cause more significant reactions.
Is there a birch pollen allergy tablet like the grass pollen tablets?
Not in the United States as of this date. Itulazax (birch pollen SLIT tablet, ALK) received EMA approval in Europe but has not been approved by the FDA. US birch-allergic patients who prefer sublingual options must use compounded SLIT drops (off-label), which are prescribed under the birch SCIT evidence base but without an FDA-approved formulation. Grastek (timothy grass), Oralair (5-grass), and Ragwitek (short ragweed) are the only FDA-approved SLIT tablets for aeroallergens in the US. A board-certified allergist can discuss compounded SLIT drops as an option for birch-allergic patients who prefer daily oral over injection-based treatment.
How is tree pollen allergy diagnosed before starting allergy shots?
Diagnosis requires documented IgE sensitization to specific tree pollens, confirmed by either a positive skin prick test (wheal ≥3mm above negative control) or a serum-specific IgE blood test (≥0.35 kUA/L threshold). Component-resolved testing — specifically ImmunoCAP Bet v 1 — clarifies whether a tree-allergic patient is primarily birch-sensitized or has independent sensitizations to other species. This distinction matters for extract selection: a Bet v 1-monosensitized patient may only need birch extract in the SCIT vial, while a patient with additional independent oak or cedar sensitization may need separate extracts. IgE testing should precede any SCIT formulation decision.
What is the schedule for tree pollen allergy shots?
Tree pollen SCIT follows the same schedule as all pollen SCIT: approximately 26–28 weekly build-up injections (Year 1 approximately 39 total visits in a conventional clinic protocol) per Cox 2011 PP3, then every 2–4 weeks for Years 2–5. Cluster schedules (Tabar 2005) can compress build-up to 7–13 visits. With Curex's at-home program, the same weekly injection schedule continues at home — first dose and every dose change supervised by your allergist live over Zoom, prescribed epinephrine auto-injector confirmed on hand, then self-administered weekly with brief self-observation. Many allergists prefer starting tree-pollen SCIT build-up in late summer or fall — after the current spring tree season ends and before the next begins — though US practice does not require off-season initiation.
Related Articles
Allergy Desensitization Therapy: Program Guide | Curex
Allergy desensitization therapy is a 3-5 year SCIT program: 24-28 weekly build-up visits, then monthly maintenance. Durham 1999 NEJM: durable remission after course ends.
Read morePollen Allergy Shot: 3-Way Triage Guide | Curex
Pollen allergy shot triage: depot steroid (discouraged), SLIT tablet, or SCIT. Curex at-home SCIT is category 3: shots weekly at home, $129/month.
Read moreMold Allergy Shots: Evidence & Limits | Curex Guide
Mold SCIT has one well-controlled RCT allergen — Alternaria (Kuna 2011: 63.5% reduction). Cladosporium, Aspergillus, Stachybotrys lack RCT support. Full honest guide.
Read moreAllergy Desensitization: Which Treatment Type? | Curex
Allergy desensitization is active allergen-specific immunotherapy (SCIT or SLIT). Differs from passive immunotherapy and pharmacotherapy in mechanism.
Read moreAllergy Shots vs Drops: Evidence-Based Comparison | Curex
Allergy shots (SCIT) vs sublingual drops (SLIT): comparable efficacy per Nelson 2015, but SLIT has zero fatalities vs 1 per 2.5M shots. Full comparison.
Read moreAllergy Shots for Seasonal Allergies | Curex Guide
Yes, allergy shots work for seasonal allergies — Cochrane 51 RCTs found symptom SMD −0.73. Learn who qualifies, what the commitment is, and what 23.9% dropout means.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.